Shapu Aisi Eye Drops has received much attention from the society. On the 9th, the reporter once again came to Zhejiang Shapu Aisi Pharmaceutical Co., Ltd. for a field visit. Wu Jianguo, secretary of the board of directors and deputy general manager of the company, said in an interview that the verification workload of relevant enterprises is very high in response to the requirements of the relevant departments. Big.
The reporter learned that Shapu Aisi was originally located in the east lake of Pinghu City, Zhejiang Province. Because the area was planned by the government as residential land, the company moved to the economic development zone at the end of 2015. Compared with the original 80-acre land, the 134-acre site now expands by more than half.
“There are currently more than 800 workers in the factory, and there are 30 to 40 R&D personnel. There are about 900 sales companies located next door. The sales staff covers the whole country according to the provinces and regions. In addition, there is a subsidiary that produces proprietary Chinese medicines. Wu Jianguo said.
Located behind the administrative building is the company's workshop, which consists of two three-storey single buildings. According to Wu Jianguo, according to the type, there are probably five or six major production workshops in the two buildings. The first floor is a large infusion workshop and the eye drop shop is located on the second floor.
When the reporter asked to go to the eye drops workshop, the other party said that the eye drops shop has high requirements for hygiene standards. Each workshop has an independent access control system, which is now inaccessible. The reporter saw that the staff on the second floor window was working in blue overalls.
During the visit, the company's chairman Chen Dekang was inquired by the Zhejiang Food and Drug Administration in Hangzhou. The company's board secretary Wu Jianguo accepted an exclusive interview with Xinhua News Agency on the current social concerns.
"There was a lot of negative news from our company during this time. The relevant departments also issued a document asking us to check. The requirements of the announcement issued by the Shanghai Stock Exchange are very detailed. The verification workload is very large. Some problems must wait until the announcement is completed before answering. "Wu Jianguo said.
When talking about the timetable for launching the clinical effectiveness trial, Wu Jianguo said that the issue is too sensitive and cannot be answered at present, and will be officially announced within the time limit set by the Shanghai Stock Exchange.
Wu Jianguo said that the company's advertising content is based on relevant laws, has been officially approved by relevant departments, and has been approved by relevant departments after questioning the alleged false propaganda and exaggeration of advertising. “These advertising content is currently being checked to see what is different and the results will be announced as soon as possible.â€
Wu Jianguo said that he did not know about the case where the previously exposed company paid bribes to the relevant departmental cadres, which is also included in the list of issues to be verified.
When the reporter proposed to visit the company's honor showroom, look at the original approval documents obtained by the company and the company's certificate of scientific and technological innovation certificate, Wu Jianguo said that these documents were kept by special personnel. According to the planning, there is a showroom on the 5th floor of the administrative building. But it is not yet enabled. (Xinhua)
Our mission: To protect the health of ear, throat and nose with medical frontier knowledge and technological innovation.
Our vision: Leader in several niche markets of Otolaryngology.
Our values: Change, Enterprising, Share
Electric Nasal Aspirator, Breast Pump, Inverted Nipple Corrector
Ningbo Jiamai Internet Technology CO., Ltd. , https://www.jmcuhyd.com